Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice

Gut

Volumn 60, Issue 12, 2011, Pages 1678-1686

  Jauch, Dominik ^a   Martin, Maria ^a   Schiechl, Gabriela ^a   Kesselring, Rebecca ^a   Schlitt, Hans Jürgen ^a   Geissler, Edward K ^a   Fichtner Feigl, Stefan ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; COLITIS; COLON TUMOR; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY TEST; DISEASE ASSOCIATION; GROWTH INHIBITION; IMMUNOSURVEILLANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; COLITIS; COLON; COLONIC NEOPLASMS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DEXTRAN SULFATE; IMMUNOLOGIC SURVEILLANCE; INTERFERON-GAMMA; INTERLEUKINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONITORING, IMMUNOLOGIC;

EID: 80655125038     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300612     Document Type: Article

References (47)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92. (Pubitemid 46359643)
2. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35. (Pubitemid 32234798)
3. Sachar DB. Cancer in Crohn's disease: dispelling the myths. Gut 1994;35:1507-8. (Pubitemid 24339242)
4. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287:G7-17.
5. Xiao H, Yin W, Khan MA, et al. Loss of single immunoglobulin interlukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice. Gastroenterology 2010;139:574-85.
6. Xiao H, Gulen MF, Qin J, et al. The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 2007;26:461-75. (Pubitemid 46602997)
7. Salcedo R, Worschech A, Cardone M, et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 2010;207:1625-36.
8. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007;317:124-7. (Pubitemid 47056471)
9. Zhang J, Stirling B, Temmerman ST, et al. Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest 2006;116:3042-9. (Pubitemid 44684489)
10. Fukata M, Chen A, Vamadevan AS, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007;133:1869-81.
11. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-13.
12. Bollrath J, Phesse TJ, von Burstin VA, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009;15:91-102.
13. Garrett WS, Punit S, Gallini CA, et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 2009;16:208-19.
14. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96. (Pubitemid 39061110)
15. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008;26:57-79. (Pubitemid 351600371)
16. Fichtner-Feigl S, Fuss IJ, Preiss JC, et al. Treatment of murine Th1- and Th2- mediated inflammatory bowel disease with NF-kappaB decoy oligonucleotides. J Clin Invest 2005;115:3057-71. (Pubitemid 41567571)
17. Fichtner-Feigl S, Fuss IJ, Young CA, et al. Induction of IL-13 triggers TGF-beta1- dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol 2007;178:5859-70. (Pubitemid 46674383)
18. Fuss IJ, Marth T, Neurath MF, et al. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999;117:1078-88. (Pubitemid 29512666)
19. Fina D, Sarra M, Fantini MC, et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008;134:1038-48.
20. Fantini MC, Rizzo A, Fina D, et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 2007;37:3155-63. (Pubitemid 350131294)
21. Fichtner-Feigl S, Terabe M, Kitani A, et al. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res 2008;68:3467-75.
22. Terabe M, Matsui S, Park JM, et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003;198:1741-52. (Pubitemid 37494166)
23. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48. (Pubitemid 39094044)
24. Kagi D, Ledermann B, Burki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994;369:31-7. (Pubitemid 24144352)
25. van den Broek ME, Kagi D, Ossendorp F, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996;184:1781-90. (Pubitemid 26404469)
26. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182-205. (Pubitemid 28307304)
27. MacDonald TT, DiSabatino A, Gordon JN. Immunopathogenesis of Crohn's disease. JPEN J Parenter Enteral Nutr 2005;29(4 Suppl):S118-24, discussion S124-5, S184-8.
28. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29. (Pubitemid 34851835)
29. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-17. (Pubitemid 40568680)
30. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;454:436-44.
31. Langowski JL, Kastelein RA, Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol 2007;28:207-12. (Pubitemid 46654872)
32. Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461-5. (Pubitemid 44264796)
33. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010;10:248-56.
34. Kryczek I, Wei S, Szeliga W, et al. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009;114:357-9.
35. Sfanos KS, Bruno TC, Maris CH, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008;14:3254-61.
36. Charles KA, Kulbe H, Soper R, et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009;119:3011-23.
37. Wurster AL, Rodgers VL, Satoskar AR, et al. Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med 2002;196:969-77.
38. Monteleone G, Monteleone I, Fina D, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005;128:687-94. (Pubitemid 40585371)
39. Sarra M, Monteleone I, Stolfi C, et al. Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis 2010;16:1332-9.
40. Siegmund B, Fantuzzi G, Rieder F, et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 2001;281:R1264-73.
41. Franciszkiewicz K, Le Floc'h A, Jalil A, et al. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res 2009;69:6249-55.
42. Berenson LS, Ota N, Murphy KM. Issues in T-helper 1 development-resolved and unresolved. Immunol Rev 2004;202:157-74.
43. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11. (Pubitemid 32391043)
44. Street SE, Trapani JA, MacGregor D, et al. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002;196:129-34. (Pubitemid 34747318)
45. Zeng R, Spolski R, Casas E, et al. The molecular basis of IL-21-mediated proliferation. Blood 2007;109:4135-42. (Pubitemid 46743374)
46. Zeng R, Spolski R, Finkelstein SE, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005;201:139-48. (Pubitemid 40130091)
47. Hinrichs CS, Spolski R, Paulos CM, et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008;111:5326-33.